Hospital
The Monroe Clinic, INC.
The Monroe Clinic, INC. was paid $6.28M by Medicaid between Jan 2018 and Dec 2024, across 225 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoTHE MONROE CLINIC, INC.
MONROE, WI 53566
MONROE, WI 53566
33aNPI1740291491assigned 08/10/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$6.28M
24GClaims351,591
24DCodes billed225
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,151 | $1.12M | |
| 2019 | 55,388 | $956K | |
| 2020 | 39,272 | $651K | |
| 2021 | 52,621 | $813K | |
| 2022 | 56,835 | $847K | |
| 2023 | 55,188 | $984K | |
| 2024incomplete | 41,136 | $906K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 15,832 | 13,272 | $778K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 11% | 26,377 | 23,158 | $700K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 7.0% | 12,883 | 4,658 | $438K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6.8% | 13,276 | 11,355 | $426K |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.6% | 4,210 | 3,109 | $415K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 4.8% | 6,941 | 5,785 | $303K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.6% | 29,962 | 19,717 | $225K |
| 92015 | Determination of refractive state | 3.6% | 5,075 | 3,990 | $223K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.4% | 3,724 | 3,284 | $216K |
| 80053 | Comprehensive metabolic panel | 3.2% | 14,369 | 11,586 | $199K |
| 90834 | Psychotherapy session, about 45 minutesPsychotherapy, 45 minutes with patient | 2.4% | 4,455 | 2,960 | $152K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.8% | 3,534 | 2,920 | $114K |
213 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 1,834 | $99K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 2,143 | $97K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 14,653 | $71K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,313 | $68K |
| 90832 | Psychotherapy session, about 30 minutes | 1.1% | 1,885 | $68K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.0% | 3,389 | $66K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,204 | $60K |
| 81001 | <1% | 4,647 | $59K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 963 | $59K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,811 | $53K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 2,379 | $53K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 839 | $52K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 951 | $49K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 698 | $47K |
| 87081 | <1% | 2,466 | $47K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,242 | $43K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,011 | $42K |
| 87631 | <1% | 401 | $42K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,323 | $42K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 724 | $41K |
| 90837 | Psychotherapy session, about an hour | <1% | 613 | $39K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,001 | $39K |
| 97162 | <1% | 1,184 | $39K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,288 | $39K |
| 92340 | Fitting of spectacles, except for aphakia; monofocal | <1% | 2,083 | $38K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,817 | $35K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,106 | $34K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,425 | $34K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,998 | $32K |
| 80061 | Lipid panel | <1% | 3,824 | $28K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,276 | $26K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 459 | $25K |
| 84484 | <1% | 4,306 | $24K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,736 | $21K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,449 | $20K |
| 81025 | <1% | 1,846 | $20K | |
| 85610 | <1% | 2,765 | $19K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 761 | $18K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 341 | $17K |
| 0002A | <1% | 442 | $16K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 410 | $14K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,131 | $14K |
| 84145 | <1% | 1,279 | $14K | |
| 0001A | <1% | 462 | $13K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 227 | $13K |
| 85027 | <1% | 3,821 | $13K | |
| 83690 | <1% | 2,987 | $12K | |
| 83605 | <1% | 2,081 | $12K | |
| 81003 | <1% | 2,541 | $11K | |
| 90686 | <1% | 1,841 | $10K | |
| 80306 | <1% | 761 | $9K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 279 | $9K |
| 82077 | <1% | 514 | $8K | |
| 83735 | <1% | 2,238 | $7K | |
| 82962 | <1% | 1,231 | $7K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 93 | $7K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 137 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 163 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 819 | $7K |
| 82565 | <1% | 409 | $6K | |
| 0004A | <1% | 189 | $6K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 480 | $6K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 126 | $6K |
| 97161 | <1% | 99 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,185 | $6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 187 | $6K |
| 97035 | <1% | 675 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,066 | $6K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 112 | $6K |
| 82948 | <1% | 1,198 | $5K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 366 | $5K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 148 | $5K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 223 | $4K |
| 84703 | <1% | 767 | $4K | |
| 99218 | <1% | 153 | $4K | |
| 82607 | <1% | 262 | $4K | |
| 87040 | <1% | 547 | $4K | |
| 85379 | <1% | 702 | $4K | |
| 0071A | <1% | 192 | $4K | |
| 83655 | <1% | 318 | $3K | |
| 20610 | <1% | 275 | $3K | |
| 0072A | <1% | 149 | $3K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 115 | $3K |
| 87186 | <1% | 829 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 624 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,505 | $2K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 34 | $2K |
| 97163 | <1% | 92 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,685 | $2K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $2K |
| 0124A | <1% | 46 | $2K | |
| 80143 | <1% | 186 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 19 | $1K |
| 87210 | <1% | 335 | $1K | |
| 0031A | <1% | 45 | $1K | |
| 80179 | <1% | 162 | $1K | |
| 87634 | <1% | 14 | $1K | |
| 90961 | <1% | 31 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 15,733 | $1K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $1K |
| 85730 | <1% | 404 | $1K | |
| 80050 | General health panel | <1% | 60 | $1K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,453 | $1K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 148 | $1K |
| 92341 | <1% | 42 | $1K | |
| 87088 | <1% | 97 | $966.58 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,790 | $961.72 |
| 84132 | <1% | 22 | $957.71 | |
| 82728 | <1% | 174 | $934.28 | |
| 86703 | <1% | 178 | $818.16 | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 22 | $762.00 |
| 90670 | <1% | 149 | $743.96 | |
| 90677 | <1% | 15 | $722.42 | |
| 85007 | <1% | 14 | $668.10 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 30 | $652.11 |
| 80055 | <1% | 57 | $642.08 | |
| V5266 | Battery for use in hearing device | <1% | 312 | $606.67 |
| 86140 | <1% | 265 | $601.84 | |
| 90651 | <1% | 58 | $586.98 | |
| 73630 | <1% | 340 | $579.92 | |
| 87070 | <1% | 104 | $557.99 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 13 | $487.63 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 812 | $467.54 |
| 83540 | <1% | 43 | $453.42 | |
| 84439 | <1% | 164 | $396.76 | |
| 90723 | <1% | 56 | $386.06 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 15 | $379.70 |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $370.07 |
| 11721 | <1% | 70 | $355.92 | |
| 83880 | <1% | 28 | $355.55 | |
| 86850 | <1% | 129 | $349.98 | |
| 87077 | <1% | 140 | $346.19 | |
| 90662 | <1% | 115 | $343.25 | |
| 84702 | <1% | 34 | $302.11 | |
| 99188 | <1% | 31 | $296.47 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 28 | $290.14 |
| 73130 | <1% | 27 | $279.84 | |
| 73610 | <1% | 138 | $276.84 | |
| 85014 | <1% | 397 | $200.31 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $193.44 |
| 90685 | <1% | 60 | $191.98 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,971 | $188.78 |
| 90734 | <1% | 25 | $187.99 | |
| 99443 | <1% | 19 | $186.18 | |
| 85652 | <1% | 163 | $180.70 | |
| 86900 | <1% | 116 | $179.71 | |
| 86901 | <1% | 113 | $176.72 | |
| 90633 | <1% | 55 | $162.19 | |
| 84450 | <1% | 68 | $152.67 | |
| 90694 | <1% | 56 | $132.88 | |
| 82570 | <1% | 87 | $109.52 | |
| 82947 | <1% | 41 | $106.11 | |
| 85018 | <1% | 211 | $105.80 | |
| 87205 | <1% | 48 | $102.30 | |
| 92551 | <1% | 12 | $101.52 | |
| 96161 | <1% | 25 | $93.66 | |
| 83550 | <1% | 14 | $81.28 | |
| 91307 | <1% | 77 | $80.03 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,571 | $78.17 |
| 82043 | <1% | 56 | $74.83 | |
| 86592 | <1% | 91 | $70.18 | |
| 82746 | <1% | 12 | $58.80 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,332 | $54.54 |
| 82550 | <1% | 17 | $53.84 | |
| 84550 | <1% | 30 | $47.62 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,062 | $47.57 |
| 90710 | <1% | 13 | $43.03 | |
| 90647 | <1% | 12 | $36.41 | |
| 96376 | <1% | 410 | $35.83 | |
| G0008 | Administration of influenza virus vaccine | <1% | 560 | $33.27 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,184 | $32.74 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 910 | $32.61 |
| 74019 | <1% | 13 | $29.08 | |
| 73564 | <1% | 68 | $24.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,329 | $23.38 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 28 | $11.86 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,922 | $10.95 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,910 | $10.87 |
| 81015 | <1% | 36 | $9.45 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 488 | $9.03 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,393 | $8.52 |
| 99152 | <1% | 62 | $7.18 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,198 | $6.09 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 432 | $2.74 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 453 | $2.17 |
| 72170 | <1% | 35 | $1.76 | |
| 91305 | <1% | 23 | $0.01 | |
| A9270 | Non-covered item or service | 0% | 663 | $0.00 |
| J3490 | Unclassified drugs | 0% | 325 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 21 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 123 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 245 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 61 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 206 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 163 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 18 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 12 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 38 | $0.00 |
| 73502 | 0% | 14 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 44 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 15 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 320 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 109 | $0.00 |
| 72100 | 0% | 16 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 155 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 195 | $0.00 |
| 36592 | 0% | 95 | $0.00 | |
| 91312 | 0% | 14 | $0.00 | |
| 73030 | 0% | 17 | $0.00 | |
| 91300 | 0% | 98 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 18 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
| A4649 | Surgical supply; miscellaneous | 0% | 222 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALKER, TROY (DIRECTOR OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Waupun Memorial Hospital | Beaver Dam, WI | $366K |
| SSM Healthcare of Wi INC | Baraboo, WI | $202K |
| Agnesian Healthcare, INC | Fond Du Lac, WI | $28K |
| SSM Health Care of Wisconsin INC | Baraboo, WI | $831.82 |
| SSM Healthcare of Wi INC | Baraboo, WI | $124.80 |
| ST Clare Imaging Services, LLC | Baraboo, WI | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.